Education
About Us
Working with TipRanks
Follow Us
Harmony Biosciences Holdings (HRMY)
NASDAQ:HRMY
RESEARCH TOOLSreports
HRMY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$26.47 - $41.61
Previous CloseN/A
Volume87.33K
Average Volume (3M)649.18K
Market Cap
$1.87B
Enterprise Value$1.49B
Total Cash (Recent Filing)$565.27M
Total Debt (Recent Filing)$172.09M
Price to Earnings (P/E)10.5
Beta1.51
Next Earnings
Nov 04, 2025EPS Estimate
0.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.68
Shares Outstanding57,532,600
10 Day Avg. Volume926,929
30 Day Avg. Volume649,180
Financial Highlights & Ratios
PEG Ratio0.75
Price to Book (P/B)2.97
Price to Sales (P/S)2.74
P/FCF Ratio8.95
Enterprise Value/Market Cap0.80
Enterprise Value/Revenue1.93
Enterprise Value/Gross Profit2.46
Enterprise Value/Ebitda5.62
Forecast
1Y Price Target
$50.71Price Target Upside58.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Bulls Say, Bears Say
Bulls Say
Drug PotentialZYN-002 holds great potential as there are no other approved drugs for Fragile X Syndrome.
Market OpportunityThe potential market for ZYN-002 is large, with a total addressable market of over $2 billion and no FDA approved treatments currently available.
Revenue GrowthHarmony reaffirmed 2025 revenue guidance of $820M–$860M, reinforcing its position as a profitable, self-funding biotech.
Bears Say
Clinical Trial RisksThere is a risk of high placebo response impacting the success of ZYN-002 in Fragile X Syndrome.
Investor SentimentInvestor expectations are low for Harmony Biosciences due to a history of failures, gel formulation issues, and an unproven mechanism of action.
Sales PerformanceHRMY reported a top-line miss, with Wakix revenue of $200.5mn below estimates.
Harmony Biosciences Holdings News
HRMY FAQ
What was Harmony Biosciences Holdings’s price range in the past 12 months?
Harmony Biosciences Holdings lowest stock price was $26.47 and its highest was $41.61 in the past 12 months.
What is Harmony Biosciences Holdings’s market cap?
Harmony Biosciences Holdings’s market cap is $1.87B.
When is Harmony Biosciences Holdings’s upcoming earnings report date?
Harmony Biosciences Holdings’s upcoming earnings report date is Nov 04, 2025 which is in 47 days.
How were Harmony Biosciences Holdings’s earnings last quarter?
Harmony Biosciences Holdings released its earnings results on Jul 31, 2025. The company reported $0.68 earnings per share for the quarter, missing the consensus estimate of $0.705 by -$0.025.
Is Harmony Biosciences Holdings overvalued?
According to Wall Street analysts Harmony Biosciences Holdings’s price is currently Undervalued.
Does Harmony Biosciences Holdings pay dividends?
Harmony Biosciences Holdings does not currently pay dividends.
What is Harmony Biosciences Holdings’s EPS estimate?
Harmony Biosciences Holdings’s EPS estimate is 0.74.
How many shares outstanding does Harmony Biosciences Holdings have?
Harmony Biosciences Holdings has 57,532,600 shares outstanding.
What happened to Harmony Biosciences Holdings’s price movement after its last earnings report?
Harmony Biosciences Holdings reported an EPS of $0.68 in its last earnings report, missing expectations of $0.705. Following the earnings report the stock price went down -0.846%.
Which hedge fund is a major shareholder of Harmony Biosciences Holdings?
Currently, no hedge funds are holding shares in HRMY
Harmony Biosciences Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$50.71 (58.17% Upside)
$50.71 (58.17% Upside)
Blogger Sentiment
Bullish
HRMY Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 164.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.3%
Last 30 Days ▲ 11.1%
Last 30 Days ▲ 11.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-16.69%
12-Months-Change
Fundamentals
Return on Equity
27.58%
Trailing 12-Months
Asset Growth
29.08%
Trailing 12-Months
Company Description
Harmony Biosciences Holdings
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
HRMY Company Deck
HRMY Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong performance by Harmony Biosciences with significant revenue growth and advancements in their clinical pipeline. The company has a robust pipeline and financial health, although there are some concerns about trade inventory reductions and potential expenses. Overall, the positive aspects significantly outweigh the challenges.View all HRMY earnings summariesHRMY Stock 12 Month Forecast
Average Price Target
$50.71
▲(58.17% Upside)
Technical Analysis
Ownership Overview
11.56% Insiders
21.36% Mutual Funds
24.12% Other Institutional Investors
17.77% Public Companies and Individual Investors